Press

Atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 14 • 2 min read

Atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. Details of the company’s participation is as follows: 2023 Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, September 28th at 1:50 P.M. ET…

Beckley Waves Raises $3.3 Million Funding Round to Expand Safe and Legal Access To Psychedelic Therapies

Sep 14 • 3 min read

Investor Interest in Care Delivery and Expanded Access Marks End of “Psychedelic Winter” Beckley Waves, the first venture studio explicitly formed to build and invest in the thriving psychedelic ecosystem to advance mental health and well-being, announced today that the company had closed a $3.3 million (10% more than their target) funding round. Investors included the…

PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease

Sep 14 • 3 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), is pleased to provide an update on the development activities of the Company’s patented reformulated enteric coated version of orally bioavailable Cepharanthine (PD-001) as a potential treatment for oncology and infectious disease. The technical transfer and development activities with Genvion Corporation are well-underway in preparation…

Clearmind Medicine : Condensed Interim Consolidated Financial Statements – Form 6-K

Sep 13 • 27 min read

Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) July 31,2023 October 31,2022 Assets Current assets Cash and cash equivalents $ 3,847,259 $ 128,777 Other receivables 108,255…

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

Sep 13 • 2 min read

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that Singular Research has initiated analyst coverage on FSD Pharma. A copy of the report can be obtained directly from the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441